Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 19c

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

You May Also Be Interested In

• Antero Resources (AR) PT Raised to $47 at Benchmark on Natural Gas Bull Case
• Alight names three executives in leaves and broker partnerships
• 'Top Pick' CoreWeave (CRWV) PT Raised to $153 at Piper Sandler